Victoria Samsonova (KPMG – an organization of independent companies providing audit, tax and consulting services – Vedomosti) said that potential investors in medical projects are paying increasing attention not only to Moscow and St. Petersburg, but also actively participating in regional expansion.
According to her, over the past six years, potential investors have asked to search only in Moscow and the region, St. Petersburg, and sometimes in Tatarstan. “Then it started to change, and they started asking to look at different areas, rank them in some way, and look at their attractiveness according to different criteria. If we look at the big medical companies like PET-Technology, Expert Group, we see that the regional expansion is very narrow, and it covers a diverse group of the regions,” Samsonova noted.
Now there are more than 610 start-ups in the field of biomedical technologies in the Skolkovo Medical Group in Russia, although in 2013 the fund worked exclusively for Moscow and St. The expert notes that earlier, the availability of basic science and medical centers had the greatest impact on emerging medical companies, so Moscow, St. Petersburg, Tomsk and Novosibirsk were the centers of attraction. Now many solutions appear in the regions due to the opportunity to try projects there. “We are looking for startups to implement and pilot them in regional clinics. Innovations are born where there is a need,” Zarubina said.
Large companies are also interested in developing their own medicines, says Stanislav Zakharov, deputy director general for economics, finance and information technology at the Center for Corporate Health at PJSC MMC Norilsk Nickel. “For Norilsk Nickel, the social component is important, it was decided to develop its own medicine, and now startups are no less important than everyone else, because we develop medicine in the region, where it is needed. This is not in Moscow, but we are trying to bring services closer to employees, For those who are in production.
It is still difficult to promote Medtech startups in the regions, says Jaroslav Markov, CEO of Tashir Medica. “Conservatism is ingrained in the healthcare industry, it is also ingrained in district healthcare regulators at the level of relevant ministries and departments, and we see the main problem in the fact that it is difficult to promote innovation in an experimental form in the districts,” the expert noted.
According to Markov, each area proceeds from such factors as the budget, the prioritization of budget items, the importance for the population, and the solution of problems brought by the introduction of a particular tool. “In Moscow, where the wealth and budget are greater, it is possible to launch such initiatives as the Medical Technology Park or, for example, projects to test the regulatory protection environment. If we look at other regions, everyone here chooses for himself what his priority is now. Somewhere We need to restore infrastructure, invest in technologies in diagnostics, somewhere we need to improve the quality of the laboratory link, and that is where we always need to move from the consumer,” Markov said.